BIOMAT Database Logo BIOMAT Database Logo

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. 2021

Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
Department of Genetics, The Life Sciences Institute, The Hebrew University, Jerusalem, Israel; SpliSense Therapeutics, Jerusalem, Givat Ram, Israel.

Antisense oligonucleotide (ASO)-based drugs for splicing modulation were recently approved for various genetic diseases with unmet need. Here we aimed to develop an ASO-based splicing modulation therapy for Cystic Fibrosis (CF) patients carrying the 3849+10 kb C-to-T splicing mutation in the CFTR gene. We have screened, in FRT cells expressing the 3849+10 kb C-to-T splicing mutation, ~30 2'-O-Methyl-modified phosphorothioate ASOs, targeted to prevent the recognition and inclusion of a cryptic exon generated due to the mutation. The effect of highly potent ASO candidates on the splicing pattern, protein maturation and CFTR function was further analyzed in well differentiated primary human nasal and bronchial epithelial cells, derived from patients carrying at least one 3849+10 kb C-to-T allele. A highly potent lead ASO, efficiently delivered by free uptake, was able to significantly increase the level of correctly spliced mRNA and completely restore the CFTR function to wild type levels in cells from a homozygote patient. This ASO led to CFTR function with an average of 43% of wild type levels in cells from various heterozygote patients. Optimized efficiency of the lead ASO was further obtained with 2'-Methoxy Ethyl modification (2'MOE). The highly efficient splicing modulation and functional correction, achieved by free uptake of the selected lead ASO in various patients, demonstrate the ASO therapeutic potential benefit for CF patients carrying splicing mutations and is aimed to serve as the basis for our current clinical development.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076722 Drug Development The entire process of bringing a new drug to the market. It includes both preclinical and clinical testing, and regulatory approval. Computational Prediction of Drug-Target Interactions,Drug Target Prediction,Medication Development,Pharmaceutical Development,Development, Drug,Development, Medication,Development, Pharmaceutical,Drug Target Predictions,Prediction, Drug Target,Target Prediction, Drug
D012326 RNA Splicing The ultimate exclusion of nonsense sequences or intervening sequences (introns) before the final RNA transcript is sent to the cytoplasm. RNA, Messenger, Splicing,Splicing, RNA,RNA Splicings,Splicings, RNA
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense

Related Publications

Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients.
October 2023, Nucleic acid therapeutics,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.
November 1998, Genomics,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
3849+10 kb C-->T mutation and disease severity in cystic fibrosis.
July 1995, Lancet (London, England),
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
3849 + 10 kb C --> T splicing mutation in Hispanic CF patients.
July 1998, Molecular genetics and metabolism,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
The 3849 + 10 kB C-->T mutation in a 21-year-old patient with cystic fibrosis.
December 1996, Ear, nose, & throat journal,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation.
July 1993, Lancet (London, England),
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study.
January 2023, Expert opinion on drug metabolism & toxicology,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
July 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
Cystic fibrosis 3849+10kb C > T mutation associated with severe pulmonary disease and male fertility.
February 1996, American journal of respiratory and critical care medicine,
Yifat S Oren, and Michal Irony-Tur Sinai, and Anita Golec, and Ofra Barchad-Avitzur, and Venkateshwar Mutyam, and Yao Li, and Jeong Hong, and Efrat Ozeri-Galai, and Aurélie Hatton, and Chen Leibson, and Liran Carmel, and Joel Reiter, and Eric J Sorscher, and Steve D Wilton, and Eitan Kerem, and Steven M Rowe, and Isabelle Sermet-Gaudelus, and Batsheva Kerem
A Case of Cystic Fibrosis With a Rare Mutation (3849 + 10 kbC > T) and Normal Sweat Chloride Levels.
April 2015, Iranian journal of pediatrics,
Copied contents to your clipboard!